Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Bemnifosbuvir/Ruzasvir - ATEA pharmaceuticals

Next Previous
X
Search
Drug Profile

Bemnifosbuvir/Ruzasvir - ATEA pharmaceuticals

Alternative Names: Ruzasvir/Bemnifosbuvir - ATEA pharmaceuticals

Latest Information Update: 12 Dec 2024

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Atea Pharmaceuticals
  • Class Amines; Antivirals; Benzoxazines; Carbamates; Cyclopropanes; Esters; Fluorinated hydrocarbons; Imidazoles; Indoles; Phosphorus compounds; Purine nucleotides; Pyrrolidines; Small molecules; Thiazoles
  • Mechanism of Action Hepatitis C virus NS 5 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Hepatitis C

Most Recent Events

  • 04 Dec 2024 Efficacy and adverse event data from phase II trial in Hepatitis C released by Atea Pharmaceuticals
  • 15 Nov 2024 Atea Pharmaceuticals plans a phase III trial for Hepatitis C, in early 2025
  • 07 Nov 2024 Atea Pharmaceuticals plans for an end of phase 2 meeting with the US Food and Drug Administration in 1Q of 2025

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top